Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The award-winning CCH Tagetik solution provides an intuitive interface, built-in financial intelligence and automated workflows that go beyond traditional CPM solutions, empowering finance teams across industries to: Complete everyday financial processes, swiftly, so that teams can focus on strategic goals Adhere to major financial regulations and simplify compliance processes Improve productivity and reduce financial close cycle time Make faster and better-informed financial decisions Sudhir Chaturvedi, President and Executive Board Member, LTIMindtree, said: "We are excited to partner with Wolters Kluwer and combine the salient features of CCH Tagetik with our domain expertise to accelerate the financial transformation initiatives of our clients with renewed rigor, agility, and efficiency
IGF-1 LR3 Reconstitution Reference (1 mg / 1,000 mcg vial) BAC water added 1 mL Concentration 1,000 mcg/mL 20 mcg dose 0.02 mL (2 units) 40 mcg dose 0.04 mL (4 units) 50 mcg dose 0.05 mL (5 units) 80 mcg dose 0.08 mL (8 units) 100 mcg dose 0.10 mL (10 units) BAC water added 2 mL Concentration 500 mcg/mL 20 mcg dose 0.04 mL (4 units) 40 mcg dose 0.08 mL (8 units) 50 mcg dose 0.10 mL (10 units) 80 mcg dose 0.16 mL (16 units) 100 mcg dose 0.20 mL (20 units) BAC water added 3 mL Concentration 333 mcg/mL 20 mcg dose 0.06 mL (6 units) 40 mcg dose 0.12 mL (12 units) 50 mcg dose 0.15 mL (15 units) 80 mcg dose 0.24 mL (24 units) 100 mcg dose 0.30 mL (30 units) Units refer to U-100 insulin syringe markings
NOW OPEN IN PRESTON BOOK NOW Energy & Focus
A novel anti-osteoporosis mechanism of VK2: interfering with ferroptosis via AMPK/SIRT1 pathway in type 2 diabetic osteoporosis
Not for human injection or clinical use
Oleoyl-L-carnitine inhibits glycine transport by GlyT2
